Antibody#Brand name#Type#Target#Approval date#Approved treatment(s)
ofatumumab#Campath#humanized#CD52#2001#B-cell chronic lymphocytic leukemia (CLL)
Atezolizumab#Tecentriq#humanized#PD-L1#2016#bladder cancer
Avelumab#Bavencio#human#PD-L1#2017#metastatic Merkel cell carcinoma
Ipilimumab#Yervoy#human#CTLA4#2011#metastatic melanoma
Alemtuzumab#Arzerra#human#CD20#2009#refractory CLL
Nivolumab#Opdivo#human#PD-1#2014#unresectable or metastatic melanoma, squamous non-small cell lung cancer, Renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, classical hodgkin lymphoma
Pembrolizumab#Keytruda#humanized#PD-1#2014#unresectable or metastatic melanoma, squamous non-small cell lung cancer (NSCLC), Hodgkin's lymphoma, Merkel-cell carcinoma (MCC), primary mediastinal B-cell lymphoma (PMBCL), stomach cancer, cervical cancer
Rituximab#Rituxan, Mabthera#chimeric#CD20#1997#non-Hodgkin lymphoma
Durvalumab#Imfinzi#human#PD-L1#2017#bladder cancer non-small cell lung cancer
